Feb 9 (Reuters) - Novartis’s (NOVN.VX) generics unit Sandoz is working on eight to 10 new biosimilar molecules to cement its position as leading maker of copycat versions of pricey biotech drugs, the unit’s head told Handelsblatt.
Feb 9 (Reuters) - Novartis’s (NOVN.VX) generics unit Sandoz is working on eight to 10 new biosimilar molecules to cement its position as leading maker of copycat versions of pricey biotech drugs, the unit’s head told Handelsblatt.
